{"id":"NCT02566369","sponsor":"Galderma R&D","briefTitle":"Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris","officialTitle":"A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-30","primaryCompletion":"2017-11-14","completion":"2017-11-14","firstPosted":"2015-10-02","resultsPosted":"2019-08-22","lastUpdate":"2019-11-12"},"enrollment":1208,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"CD5789 (trifarotene) 50μg/g cream","otherNames":[]},{"type":"DRUG","name":"Placebo cream","otherNames":[]}],"arms":[{"label":"CD5789 (trifarotene) 50μg/g Cream","type":"EXPERIMENTAL"},{"label":"Placebo Cream","type":"PLACEBO_COMPARATOR"}],"summary":"Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.","primaryOutcome":{"measure":"Investigator Global Assessment (IGA) Success Rate at Week 12","timeFrame":"From Baseline to Week 12","effectByArm":[{"arm":"CD5789 (Trifarotene) 50μg/g Cream","deltaMin":180,"sd":null},{"arm":"Placebo Cream","deltaMin":116,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":124,"countries":["United States","Canada","Germany","Hungary","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":612},"commonTop":["Application Site Irritation","Nasopharyngitis","Sunburn","Application Site Pruritis","Headache"]}}